Several TWEAK–TWEAKR-targeting therapies for malignant tumors have been developed, such as anti-TWEAK neutralizing mAb, soluble Fn14-Fc decoy protein, and anti-Fn14 mAb with promising outcomes in vitro and in vivo [46,48]. Here, TNFRSF12A is linked to cancer.